TRCT
CNTX icon

Tower Research Capital (TRC)’s Context Therapeutics CNTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Buy
29,331
+28,099
+2,281% +$57K ﹤0.01% 3724
2026
Q1 		$3.23K Sell
1,232
-8,379
-87% -$19.6K ﹤0.01% 4350
2025
Q4 		$14.1K Buy
+9,611
New +$11.2K ﹤0.01% 3367
2025
Q3 		– Sell
-7,414
Closed -$4.86K – 5265
2025
Q2 		$4.86K Sell
7,414
-5,890
-44% -$4.24K ﹤0.01% 4254
2025
Q1 		$8.14K Buy
13,304
+12,370
+1,324% +$10.8K ﹤0.01% 3915
2024
Q4 		$981 Sell
934
-6,221
-87% -$10.8K ﹤0.01% 5122
2024
Q3 		$14K Buy
+7,155
New +$15.9K ﹤0.01% 3482
2024
Q2 		– Sell
-6,357
Closed -$8.77K – 5720
2024
Q1 		$8.77K Sell
6,357
-298
-4% -$335 ﹤0.01% 3966
2023
Q4 		$7.52K Sell
6,655
-2,308
-26% -$2.48K ﹤0.01% 4608
2023
Q3 		$13.5K Buy
8,963
+3,026
+51% +$3.42K ﹤0.01% 3778
2023
Q2 		$9.5K Sell
5,937
-2,906
-33% -$2.47K ﹤0.01% 4271
2023
Q1 		$5K Sell
8,843
-14
-0.2% -$11 ﹤0.01% 4943
2022
Q4 		$6K Buy
8,857
+1,558
+21% +$1.68K ﹤0.01% 4696
2022
Q3 		$8K Buy
7,299
+4,331
+146% +$7.8K ﹤0.01% 4767
2022
Q2 		$6K Buy
2,968
+2,935
+8,894% +$5.5K ﹤0.01% 4902
2022
Q1 		$0 Sell
33
-2,021
-98% -$4.25K ﹤0.01% 6134
2021
Q4 		$6K Buy
+2,054
New +$10.2K ﹤0.01% 5013

Other funds holding CNTX

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Tower Research Capital (TRC)'s CNTX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Context Therapeutics (CNTX) stake by 2,281% in Q2 2026, buying an estimated $57K and bringing the position to 29,331 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3724.

Tower Research Capital (TRC) first reported a position in CNTX in Q4 2021 and has held it in 17 quarters since. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Tower Research Capital (TRC) held 29,331 shares of Context Therapeutics worth $16.2K as of Q2 2026.
  • Tower Research Capital (TRC) bought 28,099 Context Therapeutics shares in Q2 2026, an estimated $57K.
  • Context Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3724 holding.
  • Tower Research Capital (TRC) first reported a position in Context Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.